Enzyme involved in arachidonic acid metabolism

Enzymes involved in arachidonic acid metabolism—including cyclooxygenases (COX-1/PTGS1, COX-2/PTGS2), lipoxygenases (5-LOX/ALOX5, 12-LOX/ALOX12, 15-LOX/ALOX15), and cytochrome P450s (CYP2C8, CYP2J2, among others)—catalyze the conversion of arachidonic acid released from membrane phospholipids into a spectrum of bioactive lipid mediators such as prostaglandins, thromboxanes, leukotrienes, epoxyeicosatrienoic acids, and hydroxyeicosatetraenoic acids[1][2][5][9]. These mediators are key regulators of inflammation, vascular function, cell proliferation, and immune response, and are implicated in a range of diseases including inflammatory conditions, cardiovascular disease, cancer, and kidney disorders. Therapeutically, these enzymes are targeted by various drugs such as NSAIDs, COX-2 inhibitors, and leukotriene inhibitors. However, modulation of these pathways can be associated with significant adverse effects, especially relating to gastrointestinal, cardiovascular, and renal systems[6][7][9]. **Note:** - The provided name, "Enzymes involved in arachidonic acid metabolism," refers to a group of related enzymes, not a single molecular entity, and thus is overly broad for a canonical target designation. Each enzyme (e.g., "Cyclooxygenase-2," "5-Lipoxygenase") should be individually specified for precise targeting[1][2][5][9]. - is_incorrect: true because the query refers to a process or group, not a single chemically defined target, which is atypical for structured drug target curation.

Other names

CyclooxygenaseLipoxygenaseCytochrome P450 (specific: PTGS1, PTGS2, ALOX5, ALOX12, ALOX15, CYP2C8, CYP2J2, etc.)

Inhibition of prostaglandin and thromboxane synthesis (COX inhibition); Inhibition of leukotriene synthesis (LOX inhibition); Inhibition of EET and HETE formation (CYP inhibition)